Literature DB >> 23493768

ITP: hematology's Cosette from Les Misérables.

V Koneti Rao1.   

Abstract

In this issue of Blood, Gudbrandsdottir et al from Denmark report that in the largest multicenter cohort to date comprising newly diagnosed adults with primary immune thrombocytopenia (ITP), addition of rituximab (RTX) to high-dose dexamethasone (DEX) as first-line therapy yields higher sustained response rates.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23493768      PMCID： PMC3596958          DOI： 10.1182/blood-2013-01-477729

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.

Authors:  Donald M Arnold; Nancy M Heddle; Julie Carruthers; Deborah J Cook; Mark A Crowther; Ralph M Meyer; Yang Liu; Richard J Cook; Anne McLeod; Janet A MacEachern; Joy Mangel; David Anderson; Linda Vickars; Alan Tinmouth; Andre C Schuh; John G Kelton
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

2.  Effect of corticotrophin and cortisone on the blood in various disorders in man.

Authors:  M M WINTROBE; G E CARTWRIGHT; J G PALMER; W J KUHNS; L T SAMUELS
Journal:  AMA Arch Intern Med       Date:  1951-09

Review 3.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

Review 4.  How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment.

Authors:  Waleed Ghanima; Bertrand Godeau; Douglas B Cines; James B Bussel
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

5.  Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.

Authors:  Sif Gudbrandsdottir; Henrik Sverre Birgens; Henrik Frederiksen; Bjarne Anker Jensen; Morten Krogh Jensen; Lars Kjeldsen; Tobias Wirenfeldt Klausen; Herdis Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Ove Juul Nielsen; Torben Plesner; Stanislaw Pulczynski; Inge Helleberg Rasmussen; Dorthe Rønnov-Jessen; Hans Carl Hasselbalch
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

6.  A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

Authors:  M N Saleh; J Gutheil; M Moore; P W Bunch; J Butler; L Kunkel; A J Grillo-López; A F LoBuglio
Journal:  Semin Oncol       Date:  2000-12       Impact factor: 4.929

7.  ITP: a historical perspective.

Authors:  Roberto Stasi; Adrian C Newland
Journal:  Br J Haematol       Date:  2011-04-05       Impact factor: 6.998

8.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

9.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

10.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113
  10 in total
  1 in total

1.  Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.

Authors:  Maria Carrabba; Wilma Barcellini; Giovanna Fabio
Journal:  J Clin Immunol       Date:  2016-04-12       Impact factor: 8.317
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.